You will be provided with a research report. The body of the report will contain some citations to references.

Citations in the main text may appear in the following forms:
1. A segment of text + space + number, for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels 15"
2. A segment of text + [number], for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels[15]"
3. A segment of text + [number†(some line numbers, etc.)], for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels[15†L10][5L23][7†summary]"
4. [Citation Source](Citation Link), for example: "According to [ChinaFile: A Guide to Social Class in Modern China](https://www.chinafile.com/reporting-opinion/media/guide-social-class-modern-china)'s classification, Chinese society can be divided into nine strata"

Please identify **all** instances where references are cited in the main text, and extract (fact, ref_idx, url) triplets. When extracting, pay attention to the following:
1. Since these facts will need to be verified later, you may need to look for some context before and after the citation to ensure that the fact is complete and understandable, rather than just a simple phrase or short expression.
2. If a fact cites multiple references, then it should correspond to two triplets: (fact, ref_idx_1, url_1) and (fact, ref_idx_2, url_2).
3. For the third form of citation (i.e., where the citation source and link appear directly in the text), the ref_idx should be uniformly set to 0.
4. If the main text does not specify the exact location of the citation (for example, only the reference list is listed at the end of the article, without specifying the citation point in the text), please return an empty list.

You should return a JSON list format, where each item in the list is a triplet, for example:
[
    {
        "fact": "Text segment from the original document. Note that Chinese quotation marks should use full-width marks. And add a single backslash before the English quotation mark to make it a readable for python json module.",
        "ref_idx": "The index of the cited reference in the reference list for this text segment.",
        "url": "The URL of the cited reference for this text segment (extracted from the reference list at the end of the research report or from the parentheses at the citation point)."
    }
]

Here is the main text of the research report:
# Therapeutic Modulation of Plasma Metal Ion Concentrations in Cardiovascular Disease: Mechanistic Rationale, Clinical Trial Evidence, and Translational Feasibility

Cardiovascular diseases remain the leading cause of global morbidity and mortality. Beyond traditional neurohormonal, metabolic, and hemodynamic targets, biometal biology has emerged as an important pathophysiological factor in vascular health. Systemic metals fall into two functional categories: essential minerals such as magnesium (\(\text{Mg}^{2+}\)), potassium (\(\text{K}^+\)), calcium (\(\text{Ca}^{2+}\)), iron (\(\text{Fe}^{2+}/\text{Fe}^{3+}\)), copper (\(\text{Cu}^{2+}\)), and zinc (\(\text{Zn}^{2+}\)), which act as obligate enzymatic cofactors, structural stabilizers, and charge carriers; and xenobiotic contaminant metals, notably lead (\(\text{Pb}^{2+}\)), cadmium (\(\text{Cd}^{2+}\)), and arsenic (\(\text{As}^{3+}\)), which exert vascular toxicity even at trace concentrations [1].

The therapeutic hypothesis suggests that modulating these systemic metal concentrations—through dietary modification, oral or parenteral supplementation, pharmacologic chelation, or therapeutic phlebotomy—can reduce endothelial dysfunction, suppress oxidative stress, prevent pathologic calcification, and lower the incidence of adverse cardiovascular events [3]. However, translating molecular theory into clinical practice reveals clear differences between biological plausibility and clinical efficacy.

## Pathophysiological Determinants: Essential Biometals and Environmental Contaminants

Vascular homeostasis depends on the regulation of intracellular and extracellular concentrations of mono- and divalent cations. Disruptions in these concentration gradients impair excitation-contraction coupling, promote vascular smooth muscle cell proliferation, induce endothelial cell apoptosis, and accelerate atherogenesis.

Magnesium functions as an endogenous calcium channel antagonist. At physiological concentrations, extracellular ionized \(\text{Mg}^{2+}\) inhibits voltage-gated L-type calcium channels in vascular smooth muscle cells, modulates baseline arterial tone, and stimulates endothelial release of prostacyclin (\(\text{PGI}_2\)) and nitric oxide (\(\text{NO}\)) [7]. Depletion of plasma \(\text{Mg}^{2+}\) augments vasoconstrictor responses to angiotensin II and endothelin-1, elevates systemic peripheral resistance, promotes sustained arterial hypertension, and facilitates oxidative atheroma formation through nuclear factor-\(\kappa\text{B}\) (\(\text{NF-}\kappa\text{B}\)) signaling cascades [7]. Potassium operates similarly; increased extracellular \(\text{K}^+\) hyperpolarizes vascular smooth muscle through inwardly rectifying \(\text{K}^+\) channels and the \(\text{Na}^+/\text{K}^+\)-ATPase pump, dampening reactive oxygen species (\(\text{ROS}\)) generation and preserving endothelium-dependent vasodilation.

Iron exhibits dual cardiovascular effects. Labile plasma iron promotes oxidative damage via Fenton and Haber-Weiss chemistry, in which ferrous iron reacts with hydrogen peroxide to yield cytotoxic hydroxyl radicals:

\[\text{Fe}^{2+} + \text{H}_2\text{O}_2 \rightarrow \text{Fe}^{3+} + \text{OH}^\bullet + \text{OH}^-\]

This oxidative cascade drives the oxidative modification of low-density lipoproteins (oxLDL), encouraging scavenger receptor uptake by macrophages and driving foam cell accumulation [9]. Conversely, absolute or functional iron depletion starves cardiomyocyte mitochondria of essential iron-sulfur clusters, degrading electron transport chain complexes I, II, and III, and impairing myocardial contractility and cellular energetics [11].

Copper and zinc form the catalytic and structural foundations of copper-zinc superoxide dismutase (\(\text{Cu/Zn-SOD}\)), an essential enzymatic antioxidant defense. Free ionic \(\text{Cu}^{2+}\) can generate hydroxyl radicals, whereas zinc stabilizes cell membranes and prevents apoptosis; zinc deficiency accelerates inflammatory atherogenesis by upregulating vascular cell adhesion molecule-1 (\(\text{VCAM-1}\)) [12]. Calcium undergoes strict systemic regulation, but transient increases in ionized calcium can induce coronary artery vasospasm, accelerate platelet aggregation, and provide a mineral template that promotes vascular calcification within vulnerable atherosclerotic plaques [14].

The American Heart Association recognized nonessential contaminant metals—principally lead, cadmium, and arsenic—as independent, modifiable risk factors for cardiovascular disease, including coronary artery disease, peripheral artery disease (PAD), stroke, and heart failure [1]. Unlike essential trace minerals, these contaminant metals serve no physiological function [2]. Lead and cadmium enter vascular endothelial cells through divalent metal transporters, where they displace essential zinc and calcium cofactors from functional motifs [2]. This substitution inactivates endothelial nitric oxide synthase (\(\text{eNOS}\)), precipitating eNOS uncoupling and producing peroxynitrite (\(\text{ONOO}^-\)) instead of vascular-protective nitric oxide [2].

The resulting systemic endothelial dysfunction triggers chronic vascular inflammation, increases vascular stiffness, elevates blood pressure, alters lipid profiles, and accelerates calcific plaque progression [2]. Long-term epidemiological investigations demonstrate a linear relationship between cumulative toxic metal exposure and premature ischemic cardiovascular mortality [1].

## Modulation of Essential Mineral Concentrations: Clinical Trial Evidence

Efforts to optimize essential mineral status have focused on oral supplementation, intravenous repletion, and therapeutic depletion.

### Magnesium and Potassium Repletion

Oral magnesium administration has been evaluated as an antihypertensive and vasculoprotective therapy. A meta-analysis of 34 double-blind, randomized, placebo-controlled trials encompassing 2,028 participants demonstrated that oral magnesium supplementation at a median dose of 368 mg/day for a median duration of 3 months significantly lowered systolic blood pressure by 2.00 mmHg (\(95\%\text{ CI } [0.43, 3.58]\)) and diastolic blood pressure by 1.78 mmHg (\(95\%\text{ CI } [0.73, 2.82]\)) [5]. These hemodynamic changes were accompanied by an increase in circulating serum magnesium of 0.05 mmol/L [5]. Restricted cubic spline modeling indicated that a minimum dose of 300 mg/day for at least one month is required to elevate serum \(\text{Mg}^{2+}\) concentrations and reduce vascular tone, with the largest antihypertensive effects occurring in cohorts with baseline hypomagnesemia or unmanaged hypertension [5].

Parenteral magnesium sulfate (\(\text{MgSO}_4\)) remains the standard treatment for suppressing early afterdepolarizations in torsades de pointes ventricular tachycardia, and displays modest efficacy in suppressing postoperative atrial fibrillation following coronary bypass surgery. However, large randomized trials demonstrating that routine oral magnesium prevents chronic major adverse cardiac events (MACE) remain lacking.

Potassium modulation, delivered primarily through dietary modification or potassium-enriched salt substitutes (\(\text{KCl}\) replacing \(\text{NaCl}\)), demonstrates clinical efficacy in reducing stroke and systemic hypertension by blunting vascular smooth muscle reactivity and facilitating renal sodium excretion.

### The Iron Paradox: Deficiency Repletion vs. Overload Clearance

Cardiovascular iron therapeutics involve two distinct clinical strategies: treating cellular iron deficiency in heart failure versus reducing excess iron stores in atherogenesis.

In heart failure with reduced ejection fraction (HFrEF), approximately half of all patients experience absolute or functional iron deficiency, defined as serum ferritin \(<100\ \mu\text{g/L}\) or ferritin \(100\text{--}299\ \mu\text{g/L}\) with a transferrin saturation (TSAT) \(<20\%\) [11]. Chronic systemic inflammation increases circulating hepcidin levels, degrading ferroportin and trapping iron within enterocytes and reticuloendothelial macrophages, which prevents utilization by heart muscle cells.

Landmark randomized controlled trials—including AFFIRM-AHF, IRONMAN, and HEART-FID—have demonstrated the efficacy of high-dose intravenous iron formulations, such as ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) [11]. While individual trials differed in meeting composite primary endpoints, systematic reviews confirm that parenteral iron restores cardiomyocyte mitochondrial respiration, improves functional performance (measured by 6-minute walk distance), elevates quality of life, and reduces recurrent hospitalizations for heart failure [11]. Crucially, oral iron remains ineffective in heart failure due to persistent hepcidin-mediated intestinal malabsorption.

Conversely, the "Iron Hypothesis" proposed by Sullivan suggested that lower body iron stores explain the relative protection of premenopausal women against atherosclerosis, positing that therapeutic iron reduction in men and postmenopausal women would reduce vascular event rates by limiting free-radical generation [10]. The Veterans Affairs Cooperative Study No. 410, known as the Iron (Fe) and Atherosclerosis Study (FeAST), formally evaluated this hypothesis [4].

FeAST randomized 1,277 patients with symptomatic peripheral arterial disease to either calibrated phlebotomy (drawing blood at 6-month intervals to maintain ferritin levels between 25 and 50 ng/mL without inducing anemia) or standard care [4]. Over a mean follow-up of 4.5 years, the trial yielded neutral results: all-cause mortality occurred in 20% of the iron-reduction cohort versus 23% of controls (\(\text{hazard ratio [HR] } 0.85\), \(95\%\text{ CI } [0.67, 1.08]\), \(p=0.17\)), and the composite secondary endpoint of death, nonfatal myocardial infarction, and stroke showed no significant difference (\(\text{HR } 0.88\), \(95\%\text{ CI } [0.72, 1.07]\), \(p=0.20\)) [4].

Although exploratory post-hoc subgroup analyses suggested potential reductions in mortality among younger patients (ages 43–61) and active smokers, the primary outcome demonstrated that routine iron reduction does not reduce broad macrovascular events in atherosclerotic populations [4]. Concurrently, prospective substudies demonstrated a reduction in new visceral malignancies (\(\text{HR } 0.65\), \(95\%\text{ CI } [0.43, 0.97]\)) and cancer-specific mortality (\(\text{HR } 0.39\), \(95\%\text{ CI } [0.21, 0.72]\)), confirming biological effects on tissue proliferative environments despite the absence of macrovascular protection [9].

### Calcium Supplementation Risks and Zinc Biomarker Modulation

The safety profile of routine oral calcium supplementation for osteoporosis has been reassessed following evidence of cardiovascular risks [14]. Meta-analyses conducted by Bolland and colleagues across randomized placebo-controlled trials revealed that supplemental calcium boluses (\(\ge 500\text{ mg/day}\) elemental calcium), administered with or without vitamin D, increased the risk of incident myocardial infarction by 24% to 31% (\(\text{relative risk [RR] } 1.24\), \(95\%\text{ CI } [1.07, 1.45]\), \(p=0.004\)) and composite stroke or MI by 15% to 17% (\(\text{RR } 1.15\), \(95\%\text{ CI } [1.03, 1.27]\)) [24].

Pharmacokinetically, exogenous calcium supplements cause transient postprandial spikes in ionized serum calcium, unlike dietary calcium intake [14]. These episodic spikes can alter vascular tone, increase platelet aggregation, and accelerate microcalcification in vulnerable fibroatheromas [14]. In contrast, dietary calcium intake from food sources shows no association with heightened vascular risk, which has led clinical guidance to favor dietary optimization over routine pharmacological calcium pills [14].

With respect to zinc, meta-analyses of randomized trials indicate that supplementation reduces surrogate cardiometabolic markers, including triglycerides (\(\text{standardized mean difference } -0.66\)), total cholesterol, fasting blood glucose, and circulating markers of systemic inflammation such as high-sensitivity C-reactive protein (\(\text{hs-CRP}\)) and interleukin-6 (\(\text{IL-6}\)) [13]. Despite these biomarker improvements, long-term randomized clinical trials evaluating hard atherosclerotic outcomes (myocardial infarction, stroke, cardiovascular mortality) are absent. Furthermore, high-dose zinc supplementation carries off-target risks: because zinc and copper share intestinal enterocyte transporters (divalent metal transporter 1 and metallothionein induction), unmonitored zinc intake can induce systemic copper deficiency, leading to secondary microcytic anemia, neutropenia, and dyslipidemia.

| Metal Ion Intervention | Target Axis / Pathophysiology | Key Clinical Evidence | Observed Efficacy | Feasibility & Safety Concerns |
| --- | --- | --- | --- | --- |
| **Oral Magnesium** | Vascular tone; \(\text{eNOS}\) activation; calcium channel antagonism [5] | Meta-analysis of 34 RCTs (\(n=2,028\)) [5] | SBP \(-2.00\text{ mmHg}\); DBP \(-1.78\text{ mmHg}\); modest metabolic gains [5] | Gastrointestinal intolerance (osmotic diarrhea); hypermagnesemia in advanced renal failure |
| **Intravenous Iron (FCM/FDI)** | Mitochondrial electron transport chain; cellular energetics in HFrEF [11] | AFFIRM-AHF, IRONMAN, HEART-FID [11] | Reduced recurrent HF hospitalizations; improved 6MWD and QoL; neutral on all-cause death [11] | Costly infusion logistics; potential hypersensitivity; transient hypophosphatemia |
| **Iron Depletion (Phlebotomy)** | Free radical generation; lipid oxidation (Fenton chemistry) [9] | FeAST Trial (\(n=1,277\)) [4] | Neutral for primary vascular endpoints (\(\text{HR } 0.85\), \(p=0.17\)) [4] | Risk of iatrogenic microcytic anemia; poor compliance with serial phlebotomy [4] |
| **Oral Calcium** | Bone density maintenance vs. vascular calcium seeding [14] | Bolland et al. pooled trial-level analyses (\(n>28,000\)) [24] | Increased myocardial infarction (\(\text{RR } 1.24\)) and stroke risk (\(\text{RR } 1.20\)) [24] | Postprandial hypercalcemia; accelerated plaque calcification and thrombosis [14] |
| **Oral Zinc** | Antioxidant protection; \(\text{SOD}\) activation; insulin signaling [13] | Surrogate marker meta-analyses (\(n>1,500\)) [13] | Reductions in TG, fasting glucose, \(\text{IL-6}\); zero hard-outcome data [13] | Competes with intestinal copper absorption; risk of secondary copper-deficiency cytopenias |

## Toxic Metal Extraction and the Trajectory of Chelation Therapy

Given the atherogenic profile of toxic metals, intravenous chelation therapy with disodium ethylenediaminetetraacetic acid (\(\text{Na}_2\text{EDTA}\)) was evaluated as a strategy to remove systemic heavy metals [6]. Disodium EDTA binds polyvalent cations—most notably lead, cadmium, and calcium—forming stable coordination compounds that undergo renal excretion [29].

The initial Trial to Assess Chelation Therapy (TACT), published in 2013, evaluated 1,708 post-myocardial infarction patients aged 50 or older randomized to 40 infusions of a multi-component \(\text{Na}_2\text{EDTA}\) solution or placebo, alongside high-dose oral multivitamins/minerals or placebo [3]. TACT observed an 18% relative risk reduction in the primary composite endpoint of all-cause mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for unstable angina (\(\text{HR } 0.82\), \(95\%\text{ CI } [0.69, 0.99]\), \(p=0.035\)) [3].

This modest benefit was driven primarily by a reduction in coronary revascularization procedures [31]. In an exploratory, prespecified subgroup of 633 patients with diabetes, a 41% relative reduction in primary events was reported (\(\text{HR } 0.59\), \(95\%\text{ CI } [0.44, 0.79]\)) [29].

Despite these findings, the cardiology community remained cautious due to significant trial limitations [31]:

- A 18% trial dropout rate, with disproportionately higher consent withdrawals in the placebo group (20% vs. 13.7%) [29].
- Over-reliance on non-academic complementary medicine centers for participant enrollment [34].
- Execution of 11 sequential interim analyses, heightening the risk of false-positive statistical discoveries [34].
- Complete absence of baseline and follow-up heavy metal biomonitoring, leaving the proposed mechanism unconfirmed [29].

To rigorously test this hypothesis, the multicenter Trial to Assess Chelation Therapy 2 (TACT2) was initiated in 2016 and published in 2024 [3]. TACT2 enrolled 1,000 patients across 88 clinical sites in the United States and Canada, enriching the study population for the subgroup showing the largest benefit in TACT: patients aged 50 or older with diabetes and a history of myocardial infarction [3]. Participants were randomized to receive 40 weekly infusions of weight- and renal-adjusted \(\text{Na}_2\text{EDTA}\) chelation solution or matching placebo, combined with the factorial oral multivitamin and mineral regimen [3].

TACT2 confirmed that \(\text{Na}_2\text{EDTA}\) successfully depleted toxic metal stores: median blood lead levels in the chelation cohort dropped by 61% (from \(9.03\ \mu\text{g/L}\) to \(3.46\ \mu\text{g/L}\), \(p<0.001\)), while remaining stable in the placebo arm (\(9.3\ \mu\text{g/L}\) to \(8.7\ \mu\text{g/L}\)) [33].

However, this metal mobilization produced no discernible clinical benefit [3]:

- The primary composite endpoint occurred in 35.6% of the chelation group compared with 35.7% of the placebo group (\(\text{adjusted HR } 0.93\), \(95\%\text{ CI } [0.76, 1.16]\), \(p=0.53\)) [31].
- Cumulative 5-year primary event rates were essentially identical (45.8% for chelation vs. 46.5% for placebo) [36].
- The key secondary composite endpoint of cardiovascular death, MI, or stroke showed no significant difference between treatment arms (18.4% vs. 19.7%, \(\text{HR } 0.89\), \(95\%\text{ CI } [0.66, 1.19]\)) [31].
- All-cause mortality was equivalent between groups (17.4% vs. 17.6%, \(\text{HR } 0.96\), \(95\%\text{ CI } [0.71, 1.30]\)) [31].

Furthermore, the oral multivitamin and multimineral arm of TACT2 (published in 2025) similarly demonstrated neutral results: high-dose oral vitamin and mineral supplements failed to reduce major adverse cardiovascular events compared to placebo (\(\text{HR } 0.99\), \(95\%\text{ CI } [0.80, 1.22]\), \(p=0.91\)), while displaying a nonsignificant trend toward higher rates of myocardial infarction, stroke, or cardiovascular death (\(\text{HR } 1.30\), \(95\%\text{ CI } [0.97, 1.73]\)) [32].

The neutral outcomes in TACT2, despite successful metal reduction, stem from several key factors. First, standard cardiovascular medical therapy improved markedly between the conduct of TACT and TACT2. A substantial proportion of TACT2 patients were treated with high-intensity statins, dual antiplatelet therapy, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists [31]. These therapies provide anti-inflammatory and vascular protection that may attenuate any incremental benefit from metal clearance [31].

Second, public health measures over recent decades drove substantial declines in environmental heavy metal exposure across North America. The median baseline blood lead level in TACT2 participants was under \(1.0\ \mu\text{g/dL}\) (\(9.03\ \mu\text{g/L}\)) [31]. Extracting metals below these low ambient thresholds yields minimal biological effect, indicating that chelation cannot prevent cardiovascular events when population exposure has already dropped below pathogenic levels [31].

Finally, the prominent effect seen in the TACT diabetic subgroup likely reflected statistical noise and regression to the mean rather than a true biological difference, an interpretation reinforced by the neutral results in TACT2 [31].

Beyond systemic EDTA, alternative approaches targeting trace metals remain under investigation. The Phase IIb TRACER-HF trial assessed trientine hydrochloride, a selective copper chelator and chaperone, in patients with chronic HFrEF [12]. The trial missed its primary endpoint of reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 12 weeks, although the 300 mg dose produced transient reductions at weeks 4 and 8, prompting evaluation in hypertrophic cardiomyopathy within the TEMPEST study [12]. In peripheral vascular disease, the ongoing TACT3a trial is examining whether localized metal extraction improves perfusion in diabetic patients presenting with critical limb ischemia [39].

| Trial Name | Sample Size (\(n\)) | Target Cohort | Interventions Evaluated | Primary Outcome Endpoint | Primary Result & Hazard Ratio |
| --- | --- | --- | --- | --- | --- |
| **TACT** (2013) [29] | 1,708 | Post-MI adults \(\ge 50\) years [29] | 40 infusions \(\text{Na}_2\text{EDTA}\) vs. Placebo; \(2\times2\) oral vitamins [29] | Composite of all-cause death, MI, stroke, revascularization, angina [29] | **Positive (Modest):** \(\text{HR } 0.82\) (\(p=0.035\)); diabetic subgroup \(\text{HR } 0.59\) [cite: 29] |
| **TACT2** (Chelation, 2024) [3] | 959 | Post-MI adults with Diabetes [3] | 40 infusions \(\text{Na}_2\text{EDTA}\) vs. Placebo [3] | Composite of all-cause death, MI, stroke, revascularization, angina [3] | **Neutral:** \(\text{HR } 0.93\) (\(95\%\text{ CI } [0.76, 1.16]\), \(p=0.53\)) [31] |
| **TACT2** (Vitamins, 2025) [37] | 1,000 | Post-MI adults with Diabetes [37] | High-dose oral multivitamins/minerals (OMVM) vs. Placebo [37] | Composite of all-cause death, MI, stroke, revascularization, angina [37] | **Neutral:** \(\text{HR } 0.99\) (\(95\%\text{ CI } [0.80, 1.22]\), \(p=0.91\)) [32] |
| **FeAST** (2007) [4] | 1,277 | Symptomatic Peripheral Arterial Disease [4] | Serial phlebotomy (target ferritin 25–50 ng/mL) vs. Control [4] | All-cause mortality [4] | **Neutral:** \(\text{HR } 0.85\) (\(95\%\text{ CI } [0.67, 1.08]\), \(p=0.17\)) [4] |
| **TRACER-HF** (2023) [12] | 190 | Chronic HFrEF (\(\text{LVEF} \le 40\%\)) [12] | Trientine HCl (50, 150, 300 mg) vs. Placebo [12] | Change in NT-proBNP at 12 weeks [12] | **Neutral:** Missed primary endpoint at 12 weeks; early transient reductions noted [12] |

## Clinical Feasibility, Pharmacological Hazards, and Safety Considerations

Modulating systemic metal ion concentrations requires managing complex pharmacokinetics and avoiding disruptions to normal mineral balance. Therapeutic translation is constrained by narrow therapeutic windows, logistical burdens, and systemic toxicities.

Delivering EDTA chelation therapy involves considerable logistical demands. The standard trial protocol requires 40 distinct intravenous infusions, each administered over 3 to 4 hours, spanning up to a year of weekly and biweekly appointments [30]. In TACT2, only 68% of participants completed the full 40-infusion regimen, illustrating the high participant burden, clinical resource allocation, and direct medical costs of this strategy [31].

The pharmacological administration of EDTA presents distinct clinical safety hazards. The United States Food and Drug Administration issued repeated Public Health Advisories warning against confusing disodium EDTA (\(\text{Na}_2\text{EDTA}\)) with calcium disodium versenate (\(\text{CaNa}_2\text{EDTA}\)) [41]. While \(\text{CaNa}_2\text{EDTA}\) is saturated with calcium and used to treat acute lead intoxication, uncomplexed \(\text{Na}_2\text{EDTA}\) binds circulating ionized calcium [41]. Rapid or unmonitored infusion of \(\text{Na}_2\text{EDTA}\) precipitates sudden, severe hypocalcemia, causing tetany, refractory cardiac arrhythmias, prolonged QT intervals, and cardiac arrest [41].

These severe adverse events prompted regulatory authorities to revoke the indications for \(\text{Na}_2\text{EDTA}\), rendering contemporary applications dependent on compounding pharmacies [45]. Furthermore, because EDTA is cleared via glomerular filtration, heavy metal-chelate complexes directly challenge the renal tubular epithelium, risking acute tubular necrosis and necessitating frequent creatinine clearance monitoring and dose titration [3].

EDTA also lacks absolute ion specificity. Alongside toxic lead and cadmium, it accelerates the urinary excretion of essential trace minerals, including zinc, manganese, and copper, which can induce secondary deficiencies if not countered with oral mineral supplementation [30].

Strategies targeting essential metals carry parallel safety considerations. Excretion of potassium and magnesium relies entirely on intact renal parenchyma. In patients with chronic kidney disease or those receiving renin-angiotensin-aldosterone system inhibitors (such as ACE inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors) or mineralocorticoid receptor antagonists, systemic supplementation can precipitate life-threatening hyperkalemia or hypermagnesemia, with risks of heart block, loss of deep tendon reflexes, and cardiac arrest.

Conversely, therapeutic iron depletion via phlebotomy carries risks of over-titration [4]. In the FeAST trial, maintaining ferritin levels between 25 and 50 ng/mL required regular laboratory monitoring to prevent excessive reduction of total hemoglobin, which risks precipitating iatrogenic iron-deficiency anemia, tissue hypoxia, and exacerbations of baseline angina or intermittent claudication [4].

## Professional Guidelines and Clinical Consensus

Major professional cardiology guidelines maintain a clear distinction between substantiated, indication-specific biometal therapies and unproven experimental applications.

The 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease provides clear guidance on chelation therapy [47]:

- Disodium EDTA chelation is not approved by the FDA for the prevention or treatment of cardiovascular disease [47].
- Chelation therapy is explicitly not recommended for clinical use outside authorized research protocols [47].
- Health insurance programs and commercial payers classify off-label chelation for coronary atherosclerosis as not medically necessary, noting the absence of reliable evidence demonstrating clinical benefit [35].

The 2023 American Heart Association Scientific Statement on Contaminant Metals established that environmental lead, cadmium, and arsenic are independent cardiovascular risk factors [2]. However, the statement emphasized that mitigation strategies must center on public health policy and primary environmental abatement—including replacing lead service lines, enforcing industrial emissions limits, and reducing soil and agricultural runoff—rather than individual clinical chelation therapy [2]. The neutral results of TACT2 confirm that individual heavy metal extraction does not provide effective secondary prevention for ischemic cardiovascular disease [3].

Current clinical guidelines from the American College of Cardiology, American Heart Association, and European Society of Cardiology establish clear distinctions regarding iron management in heart failure:

- Intravenous iron repletion using ferric carboxymaltose or ferric derisomaltose holds a Class IIa recommendation for symptomatic patients with HFrEF and documented iron deficiency to improve functional capacity, quality of life, and reduce heart failure hospitalizations.
- Oral iron supplementation is classified as ineffective (Class III: No Benefit) due to poor absorption driven by elevated hepcidin concentrations.
- Therapeutic iron depletion via phlebotomy is indicated solely for hereditary hemochromatosis with iron-overload cardiomyopathy, and has no established therapeutic role in broad coronary or peripheral vascular disease [4].

## Conclusions and Translational Perspectives

Clinical evaluations of metal ion modulation in cardiovascular disease illustrate contrasting outcomes across different therapeutic targets:

The hypothesis that non-targeted heavy metal chelation prevents macrovascular events in coronary disease has been disproven by the definitive results of TACT2 [3]. While the initial TACT trial suggested a modest signal of benefit driven by revascularization endpoints in a diabetic subgroup, the prospective replication trial demonstrated that reducing blood lead levels in patients with diabetes and prior myocardial infarction yields no reduction in death, recurrent infarction, stroke, or revascularization [29]. Modern guideline-directed secondary prevention, coupled with broad secular declines in population lead exposure, has eliminated any residual benefit chelation might have offered [31]. Consequently, EDTA chelation therapy has no role in contemporary cardiovascular prevention or treatment [47].

Conversely, targeted biometal modulation demonstrates success when addressing specific intracellular metabolic deficiencies [11]. Parenteral iron repletion in heart failure bypasses inflammatory absorption blocks to restore cardiomyocyte mitochondrial energetics, alleviating symptoms and lowering rehospitalization rates [11]. Similarly, acute intravenous magnesium repletion remains standard practice for early afterdepolarization arrhythmias, such as torsades de pointes.

Finally, non-targeted mineral supplementation presents distinct clinical risks. Regular bolus oral calcium supplementation carries paradoxical increases in the risk of myocardial infarction and stroke, likely mediated by postprandial hypercalcemia and accelerated plaque calcification [14]. High-dose oral multivitamin and mineral supplementation similarly provides no macrovascular protection [32]. These findings underscore that essential mineral balance is best supported through whole-food dietary patterns, while pharmacological metal interventions must remain restricted to substantiated, guideline-directed indications.

## References

[1] Contaminant Metals as Cardiovascular Risk Factors — https://www.ahajournals.org/doi/abs/10.1161/JAHA.123.029852
[2] Contaminant Metals as Cardiovascular Risk Factors — https://www.ahajournals.org/doi/10.1161/JAHA.123.029852
[3] Trial to Assess Chelation Therapy 2 (TACT2) - BioLINCC — https://biolincc.nhlbi.nih.gov/studies/tact2/
[4] Reduction of iron stores and cardiovascular outcomes in patients — https://pubmed.ncbi.nlm.nih.gov/17299195/
[5] Effects of Magnesium Supplementation on Blood Pressure: A Meta — https://www.researchgate.net/publication/305219864_Effects_of_Magnesium_Supplementation_on_Blood_Pressure_A_Meta-Analysis_of_Randomized_Double-Blind_Placebo-Controlled_Trials
[6] Contaminant Metals and Heart Disease | PDF | Arsenic - Scribd — https://www.scribd.com/document/662151707/JAHA-123-029852
[7] Magnesium Supplementation and Blood Pressure: A Systematic — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.125.25129
[8] Effects of Magnesium Supplementation on Blood Pressure — https://scholarworks.indianapolis.iu.edu/server/api/core/bitstreams/130f35fe-44b1-4550-a64b-de5bab878ef8/content
[9] Decreased Cancer Risk After Iron Reduction in Patients With ... - Ovid — https://www.ovid.com/journals/jnci/pdf/00005042-200807160-00010~decreased-cancer-risk-after-iron-reduction-in-patients-with
[10] Iron: Protector or Risk Factor for Cardiovascular Disease? Still — https://www.mdpi.com/2072-6643/5/7/2384
[11] Intravenous Ferric Carboxymaltose in Heart Failure With Iron ... - PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC11955906/
[12] Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed — https://www.tctmd.com/news/could-copper-chelation-benefit-hfref-tracer-hf-offers-mixed-clues
[13] Zinc supplementation and cardiovascular disease risk factors — https://pubmed.ncbi.nlm.nih.gov/37399684/
[14] 89517c86399ee7c368e3e07319 — https://archivesofrheumatology.org/plugins/generic/pdfJsViewer/pdf.js/web/viewer.html?file=https%3A%2F%2Farchivesofrheumatology.org%2Findex.php%2Fpub%2Farticle%2Fdownload%2F472%2F638%2F598
[15] Contaminant Metals as Cardiovascular Risk Factors: A Scientific — https://pure.johnshopkins.edu/en/publications/contaminant-metals-as-cardiovascular-risk-factors-a-scientific-st/
[16] Effects of Magnesium Supplementation on Blood Pressure - PubMed — https://pubmed.ncbi.nlm.nih.gov/27402922/
[17] What new evidence is available regarding intravenous iron — https://dig.pharmacy.uic.edu/faqs/2024-2/may-2024-faqs/what-new-evidence-is-available-regarding-intravenous-iron-replacement-in-patients-with-heart-failure/
[18] IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees — https://www.tctmd.com/news/iv-iron-hf-misses-again-heart-fid-meta-analysis-sees-role
[19] Effect of controlled reduction of body iron stores on clinical outcomes — https://jeffreydachmd.com/wp-content/uploads/2013/04/Effect-of-controlled-reduction-of-body-iron-stores-on-clinical-outcomes-in-peripheral-arterial-disease-ZACHARSKI-Leo-2011.pdf
[20] The Statin–Iron Nexus: Anti-Inflammatory Intervention for Arterial — https://pmc.ncbi.nlm.nih.gov/articles/PMC3673278/
[21] (PDF) Reduction of iron stores and clinical outcomes in peripheral — https://www.researchgate.net/publication/236070814_Reduction_of_iron_stores_and_clinical_outcomes_in_peripheral_arterial_disease_outcome_comparisons_in_smokers_and_non-smokers
[22] Iron reduction via periodic calibrated phlebotomy to target ferritin — https://www.researchgate.net/publication/398000159_Iron_reduction_via_periodic_calibrated_phlebotomy_to_target_ferritin_lowers_cancer_incidence_and_mortality_in_patients_with_peripheral_artery_disease_further_insights_from_the_FeAST_trial
[23] Effect of calcium supplements on risk of myocardial infarction ... - NCBI — https://www.ncbi.nlm.nih.gov/books/NBK79480/
[24] Calcium supplements with or without vitamin D and risk of ... - The BMJ — https://www.bmj.com/content/342/bmj.d2040
[25] Calcium supplements with or without vitamin D and risk of ... - The BMJ — https://www.bmj.com/content/bmj/342/bmj.d2040.full.pdf
[26] Effect of calcium supplements on risk of myocardial infarction and — https://pubmed.ncbi.nlm.nih.gov/20671013/
[27] Long term calcium intake and rates of all cause and cardiovascular — https://www.bmj.com/content/346/bmj.f228
[28] Effects of Zinc Supplementation on Cardiometabolic Risk Factors — https://pubmed.ncbi.nlm.nih.gov/31494808/
[29] The trial to assess chelation therapy 2 (TACT2): Rationale and design — https://www.ovid.com/journals/amhj/pdf/10.1016/j.ahj.2022.05.013~the-trial-to-assess-chelation-therapy-2-tact2-rationale-and
[30] Pharmacokinetics of metal excretion following different doses ... - PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC12050972/
[31] Trial to Assess Chelation Therapy 2 - TACT2 — https://www.acc.org/latest-in-cardiology/clinical-trials/2024/04/05/04/40/tact2
[32] In patients with diabetes and previous MI, high-dose multivitamins — https://www.acpjournals.org/doi/10.7326/ANNALS-25-02174-JC
[33] EDTA Chelation No Help in Cutting CV Outcomes After MI in — https://www.tctmd.com/news/edta-chelation-no-help-cutting-cv-outcomes-after-mi-diabetic-patients-tact2
[34] Study Gets to the Heart of Controversial Chelation Therapy — https://www.mcgill.ca/oss/article/medical/study-gets-heart-controversial-chelation-therapy
[35] Chelation Therapy - Medical Policies — https://al-policies.exploremyplan.com/portal/documents/107645/156560/Chelation%20Therapy/3098baa7-e7b1-9cde-aa44-47a6fbabb93b?version=4.0
[36] "Edetate Disodium-Based Chelation for Patients With a Previous — https://scholarlycommons.henryford.com/cardiology_articles/1319/
[37] Multivitamins After Myocardial Infarction in Patients With Diabetes — https://www.researchgate.net/publication/389519790_Multivitamins_After_Myocardial_Infarction_in_Patients_With_Diabetes_A_Randomized_Clinical_Trial
[38] Protein Kinases in Copper Homeostasis: A Review on Cu + ... - MDPI — https://www.mdpi.com/2813-3757/2/3/15/review_report
[39] The Effect of EDTA-based Chelation on Patients with Diabetes and — https://pmc.ncbi.nlm.nih.gov/articles/PMC6557676/
[40] Limb Preservation Using Edetate Disodium-based Chelation in — https://pmc.ncbi.nlm.nih.gov/articles/PMC6986468/
[41] Edetate CALCIUM Disodium | Drug Lookup | Pediatric Care Online — https://publications.aap.org/pediatriccare/drug-monograph/18/5664/Edetate-CALCIUM-Disodium
[42] Edetate calcium disodium (calcium EDTA): Pediatric drug information — https://karte.mn/UpToDate/d/topic.htm?path=edetate-calcium-disodium-calcium-edta-pediatric-drug-information
[43] Edetate Calcium Disodium in: Pediatric Injectable Drugs — https://publications.ashp.org/abstract/book/9781585287192/ch107.xml
[44] Chelation Therapy - BlueCross BlueShield of Tennessee — https://www.bcbst.com/mpmanual/Chelation_Therapy.htm
[45] Chelation Therapy for Off-Label Uses — https://employer.myhealthtoolkitex.com/web/public/brands/medicalpolicyhb/external-policies/chelation-therapy-for-off-label-uses/
[46] Chelation Therapy for Off-Label Uses — https://employer.myhealthtoolkitvt.com/web/public/brands/medicalpolicy/external-policies/chelation-therapy-for-off-label-uses/
[47] Chelation Therapy - Special Subjects - Merck Manuals — https://www.merckmanuals.com/professional/special-subjects/integrative-complementary-and-alternative-medicine/chelation-therapy
[48] New ACC, AHA, Multi-Society Guideline Addresses Management of — https://www.acc.org/latest-in-cardiology/articles/2023/07/19/12/19/new-acc-aha-multi-society-guideline-addresses-management-of-chronic-coronary-disease-gl-ccd
[49] Chelation therapy, an established treatment for heavy metal — https://www.bcbsri.com/providers/sites/providers/files/policies/2026/05/Chelation%20Therapy%20for%20Off-Label%20Uses%20Effective%209-1-26.pdf
[50] Chelation therapy, an established treatment for heavy metal — https://www.bcbsri.com/providers/medicalpolicies/files/chelation-therapy-label-uses


Please begin the extraction now. Output only the JSON list directly, without any chitchat or explanations.